Holen Sie sich die Stockscreener-App
0.3277
4.74%
-0.0163
Vorhandelsmarkt:
.33
0.0023
+0.70%
Schlusskurs vom Vortag:
$0.344
Offen:
$0.34
24-Stunden-Volumen:
2.75M
Relative Volume:
0.50
Marktkapitalisierung:
$12.90M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-27.04M
KGV:
-0.166
EPS:
-1.9743
Netto-Cashflow:
$-17.53M
1W Leistung:
-18.68%
1M Leistung:
-35.62%
6M Leistung:
-86.23%
1J Leistung:
-91.93%
1-Tages-Spanne:
$0.3251
$0.35
1-Wochen-Bereich:
$0.2899
$0.446
52-Wochen-Spanne:
$0.2899
$8.94
Medicus Pharma Ltd Stock (MDCX) Company Profile
Firmenname
Medicus Pharma Ltd
Sektor
Telefon
610-540-7515
Adresse
300 CONSHOHOCKEN STATE RD., W. CONSHOHOCKEN
Compare MDCX vs LLY, JNJ, ABBV, AZN, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MDCX
Medicus Pharma Ltd
|
0.3277 | 12.90M | 0 | -27.04M | -17.53M | -1.9743 |
LLY
Lilly Eli Co
|
903.02 | 806.72B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
226.16 | 544.73B | 96.36B | 21.04B | 19.70B | 8.6488 |
ABBV
Abbvie Inc
|
205.12 | 362.81B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
195.78 | 303.62B | 58.80B | 10.24B | 8.98B | 3.2788 |
NVS
Novartis Ag Adr
|
147.97 | 282.35B | 54.72B | 14.02B | 15.32B | 7.1855 |
Medicus Pharma Ltd Aktie (MDCX) Neueste Nachrichten
Exclusive: Penny stock Medicus Pharma findings support potential in women's health pipeline - MSN
Medicus Pharma (MDCX) asks shareholders to approve up to 50-for-1 reverse split - Stock Titan
Medicus Pharma to Present Phase 1 Data on Teverelix at AACE 2026 - MyChesCo
Medicus Pharma Is Maintained at Buy by D. Boral Capital - Moomoo
Medicus Pharma files Orphan Drug application for SkinJect in rare skin Cancer indication - Proactive financial news
Medicus Pharma on Bloomberg World - The Northwest Florida Daily News
New to The Street to Broadcast Tonight on Bloomberg at 6:30 PM ESTShow #744 Featuring Virtuix Holdings (NASDAQ:VTIX), Neonc Technologies Holdings (NASDAQ:NTHI), Medicus Pharma (NASDAQ:MDCX), YY Group Holding (NASDAQ:YYGH), and Viv - ChartMill
Small cap wrap: HIVE Digital Technologies, Medicus Pharma, Trillion Energy... - Proactive financial news
Medicus Pharma submits orphan drug application for skin cancer treatment By Investing.com - Investing.com South Africa
Medicus Pharma seeks orphan drug status for SkinJect in rare skin cancer disorder - Yahoo! Finance Canada
Medicus Pharma (MDCX) submits ODD application for SkinJect - grafa.com
Medicus Pharma Ltd. (MDCX) has officially submitted an application to the U.S. Food and Drug Administration (FDA) seeking orphan drug designation for its innovative drug Skinject®, with the indication for Gorlin Syndrome (Basal Cell Nevus Syndrome). - Bitget
Medicus Pharma submits orphan drug application for skin cancer treatment - Investing.com
Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome - The Manila Times
Medicus Pharma to Present Phase 1 Teverelix Data at Endocrinology Meeting - MyChesCo
Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement - Petoskey News-Review
EXCLUSIVE: Penny Stock Medicus Pharma Findings Support Potential In Women's Health Pipeline - Sahm
Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony - Argus Leader
Checking In Early | See Why (Nasdaq: MDCX) Just Hit Our Morning Radar - myemail.constantcontact.com
Small cap wrap: Power Metallic Mines, EnWave, Sonoro Gold, Medicus Pharma… - Proactive financial news
Medicus Pharma Showcases Long-Acting Teverelix Data, Targets Precision Endometriosis Therapy - TipRanks
Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone ... - Caledonian Record
Hormone suppression lasting weeks: Medicus to show Teverelix data - Stock Titan
Medicus Pharma to present new Teverelix data at upcoming endocrinology meeting - Proactive financial news
EPS Watch: What is the dividend yield of Medicus Pharma Ltd Equity WarrantEarnings Risk Summary & Technical Confirmation Trade Alerts - baoquankhu1.vn
Aug Weekly: Can Medicus Pharma Ltd Equity Warrant disrupt its industryWeekly Market Summary & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
US Stocks Recap: Is Medicus Pharma Ltd Equity Warrant subject to activist investor interestForecast Cut & Low Risk Investment Opportunities - baoquankhu1.vn
New to The Street to Broadcast on Fox Business on Monday, April 13, Featuring Virtuix Holdings (NASDAQ:VTIX), Medicus Pharma (NASDAQ - marketscreener.com
New to The Street to Broadcast on Fox Business on Monday, April 13, Featuring Virtuix Holdings (NASDAQ:VTIX), Medicus Pharma (NASDAQ:MDCX), YY Group Holdings (NASDAQ:YYGH), Vivos Therapeutics (NASDAQ:VVOS), and Stardust Power (NASDAQ - Moomoo
Medicus Pharma gives Teverelix Phase 2 FDA update – ICYMI - Proactive financial news
MDCX Forecast, Price Target & Analyst Ratings | MEDICUS PHARMA LTD (NASDAQ:MDCX) - ChartMill
New to The Street Signs Medicus Pharma Ltd. (NASDAQ:MDCX) to Transformational 12-Part National Media Series Highlighting SkinJect(TM) and Teverelix(R) Platforms - ACCESS Newswire
Medicus Clarifies Phase 2 Results for SkinJect Cancer Therapy - MyChesCo
Medicus Pharma Ltd. (MDCX) stock price, news, quote and history - Yahoo Finance Australia
Medicus Pharma Submits Phase 2 Protocol for Teverelix to FDA - MyChesCo
Medicus Pharma Ltd (MDCX) Stock Price, Quote, News & History - Benzinga
Medicus Pharma submits optimized Phase 2 study design for Teverelix - Proactive financial news
Market movers: Virgin Galactic, Soleno Therapeutics, Medicus Pharma... - Proactive financial news
Medicus Pharma Streamlines Phase 2 Teverelix Trial for $2 Billion AUR Market - TipRanks
Medicus Pharma submits optimized Phase 2 Teverelix trial protocol to FDA - Yahoo Finance
Medicus targets recurrent urinary retention with 126-patient study - Stock Titan
Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention - ChartMill
EXCLUSIVE: Medicus Pharma Refines Trial Design To Cut Costs, Accelerate Development For Enlarged Prostate - Benzinga
Finanzdaten der Medicus Pharma Ltd-Aktie (MDCX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.76%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):